EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of nanobody-conjugated LL37 for synergistic therapy against MDR Acinetobacter baumannii

Apisitt Thaiprayoon, Worrapoj Oonanant iD, Siriphan Boonsilp, Nonth Submunkongtawee, Phoomintara Longsompurana, Duangtip Moonmangmee, Pinpunya Riangrungroj, Jeerapond Leelawattanachai, Lueacha Tabtimmai, Andrew C Kruse, Matthew P DeLisa, Phattara-Orn Havanapan und 1 weitere

mSphere · 2026

DOI: 10.1128/msphere.00779-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, 2026. Verfasst von Apisitt Thaiprayoon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Biological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, Thailand. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Single-Domain Antibodies, Drug Resistance, Multiple, Bacterial, Cathelicidins. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thailand Science Research and Innovation, National Research Council of Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug resistance (MDR) of the pathogen Acinetobacter baumannii is a major challenge to global healthcare due to the limited treatment options. The emergence of MDR bacteria necessitates innovative therapeutic approaches, especially given the associated economic burden and the rapid spread of infections. Conventional treatments such as antibiotics and vaccines face significant obstacles. Antimicrobial peptides (AMPs) such as LL37 have potential as an alternative treatment due to their broad-spectrum activity and ability to target specific bacterial structures such as the outer membrane protein A (OmpA). The efficacy of AMPs can be enhanced by using nanobodies (Nbs) that bind to bacterial OmpA, guiding LL37 precisely to its target. In this study, A. baumannii OmpA (AbOmpA)-specific Nbs (NbO7 and NbO13) were efficiently isolated through magnetic-activated cell sorting-based screening of a yeast surface display library, eliminating the need for specialized equipment. Nbs exhibited specific, dose-dependent binding to the target. Conjugation of Nbs with LL37 effectively inhibited the growth of MDR A. baumannii . This approach leverages the natural antimicrobial properties of AMPs and enhances their specificity and effectiveness by targeting bacterial cell surface proteins. LL37-conjugated AbOmpA-Nbs present a promising therapeutic strategy against MDR A. baumannii and other resistant pathogens. IMPORTANCE Multidrug-resistant (MDR) Acinetobacter baumannii poses a major global health threat due to its resistance to nearly all available antibiotics and its persistence in hospital settings. This challenge underscores the urgent need for new therapeutic approaches beyond conventional drugs. In this study, we developed an innovative strategy that combines the human antimicrobial peptide LL37 with nanobodies (Nbs) targeting the outer membrane protein A (OmpA), a key virulence and survival factor of A. baumannii . OmpA-specific Nbs were efficiently isolated from a fully synthetic library using a simple, low-cost selection approach without animal immunization. When conjugated with LL37, these Nbs bound specifically to OmpA and strongly inhibited MDR A. baumannii growth in vitro . Our findings introduce a simple yet powerful platform for generating targeted Nb-peptide conjugates, offering strong potential for adaptation against other antibiotic-resistant pathogens and contributing to the development of next-generation biologics to overcome antibiotic limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiSingle-Domain AntibodiesDrug Resistance, Multiple, BacterialCathelicidinsAnti-Bacterial AgentsBacterial Outer Membrane ProteinsAcinetobacter InfectionsMicrobial Sensitivity TestsHumansAntimicrobial Cationic Peptides

Stichwörter der Autor:innen

Acinetobacter baumanniiLL37MACS-based yeast displayconjugated nanobodydrug-resistance bacteriananobodyouter membrane protein A

Substanzen

Single-Domain AntibodiesCathelicidinsBacterial Outer Membrane ProteinsOMPA outer membrane proteinsAnti-Bacterial AgentsAntimicrobial Cationic Peptides

Autor:innen und Institutionen

  • Biological Engineering Program, Faculty of Engineering, King Mongkut's University of Technology Thonburi, Bangkok, Thailand.
  • Department of Basic Medical Science, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
  • Department of Clinical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
  • Department of Microbiology, Faculty of Science, King Mongkut's University of Technology Thonburi, Bangkok, Thailand.
  • National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Khlong Nueng, Pathum Thani, Thailand.
  • National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Khlong Luang, Pathum Thani, Thailand.

ORCID-Profile: Worrapoj Oonanant, Dujduan Waraho-Zhmayev

Förderung

  • Thailand Science Research and Innovation
  • National Research Council of Thailand

Zitieren

APA

Thaiprayoon, A., Oonanant, W., Boonsilp, S., Submunkongtawee, N., Longsompurana, P., Moonmangmee, D., Riangrungroj, P., Leelawattanachai, J., Tabtimmai, L., Kruse, A. C., DeLisa, M. P., Havanapan, P., & Waraho-Zhmayev, D. (2026). Development of nanobody-conjugated LL37 for synergistic therapy against MDR Acinetobacter baumannii. mSphere. https://doi.org/10.1128/msphere.00779-25

Vancouver

Thaiprayoon A, Oonanant W, Boonsilp S, Submunkongtawee N, Longsompurana P, Moonmangmee D, et al. Development of nanobody-conjugated LL37 for synergistic therapy against MDR Acinetobacter baumannii. mSphere. 2026. doi:10.1128/msphere.00779-25

BibTeX
@article{Thaiprayoon2026,
  author = {Thaiprayoon, Apisitt and Oonanant, Worrapoj and Boonsilp, Siriphan and Submunkongtawee, Nonth and Longsompurana, Phoomintara and Moonmangmee, Duangtip and Riangrungroj, Pinpunya and Leelawattanachai, Jeerapond and Tabtimmai, Lueacha and Kruse, Andrew C and DeLisa, Matthew P and Havanapan, Phattara-Orn and Waraho-Zhmayev, Dujduan},
  title = {Development of nanobody-conjugated LL37 for synergistic therapy against MDR Acinetobacter baumannii},
  journal = {mSphere},
  year = {2026},
  doi = {10.1128/msphere.00779-25}
}
Kostenlos starten →